Evidence-based guidelines for treatment of uterine body neoplasm in Japan: Japan Society of Gynecologic Oncology (JSGO) 2009 edition
- 325 Downloads
Endometrial carcinoma is one of the most common gynecologic malignancies in Japan and its incidence has increased recently. Although surgery is the cornerstone of the management of patients with endometrial cancer, there is significant variation in Japan with regard to the type of hysterectomy employed. Additionally, it remains controversial whether full nodal staging is required in all patients. Furthermore, adjuvant therapy differs between Japan and Western countries. To delineate clearly the standard of care for endometrial cancer treatment in Japan, the guidelines for the treatment of endometrial cancer were published in 2006 and revised in 2009. The 2009 edition included topics not addressed in the previous edition including the treatment of mesenchymal tumors, for example leiomyosarcoma, and sections covering the treatment of serous and clear-cell adenocarcinoma. These guidelines are composed of nine chapters and include nine algorithms. The guidelines also contain fifty-one clinical questions (CQs) and each CQ consists of recommendations, background, explanations, and references. The treatment recommendations herein are tailored to reflect current Japanese clinical practice and ensure equitable care for all Japanese women diagnosed with endometrial cancer.
KeywordsEndometrial cancer Clinical practice guidelines Surgery Chemotherapy Irradiation
We thank the Japan Society of Obstetrics and Gynecology, Japan Association of Obstetricians and Gynecologists, Japanese Gynecologic Oncology Group, and Japan Society of Clinical Oncology for their comments and contributions throughout the project. We also thank Dr Ryoichi Nagatomi (Department of Medicine and Science in Sports and Exercise, Tohoku University) for his pointed advice in the translation.
Conflict of interest
M. Mikami received a research funding from Mitsubishi Chemical Group Science and Technology Research Center, Inc., and N. Katsumata has received honoraria from Sanofi–aventis, Kyowa Hakko Kirin, Chugai Pharmaceutical, Yakult Honsha, Nippon Kayaku, and Ono Pharmaceutical. The other authors have no conflict of interest.
- 2.National Comprehensive Cancer Network (NCCN) Clinical practice guidelines in oncology. http://www.nccn.org/
- 3.Watanabe Y, Aoki D, Kitagawa R et al (2007) Status of surgical treatment procedures for endometrial cancer in Japan: results of a Japanese Gynecologic Oncology Group Survey Gynecologic. Oncology 105:325–328Google Scholar
- 6.Lurain JR (2002) Uterine cancer. In: Berek JS (ed) Novak’s gynecology, 13th edn. Lippincott Williams & Wilkins, Philadelphia, pp 1143–1147Google Scholar